Programmed death-ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) expression in bladder cancer (BC): Differences in recurrent, progressive, and metastatic disease.

Authors

null

Axel Hegele

Department of Urology and Pediatric Urology, University of Marburg, Marburg, Germany

Axel Hegele , Franziska Wahl , Peter Rexin , W Nimphius , Rainer Hofmann , Joerg Haenze

Organizations

Department of Urology and Pediatric Urology, University of Marburg, Marburg, Germany, Department of Urology, Philipps University Marburg, Marburg, Germany, Institute of Pathology, Philipps University, Marburg, Germany, Institute of Pathology, Phlipps-University, Marburg, Germany, Department of Urology, University Hospital Marburg, Marburg, Germany, Department of Urology, Philipps University, Marburg, Germany

Research Funding

Other

Background: The significance of PD-L1/PD-1 expression in BC is still unclear. In the present study we evaluated the PD-L1/PD-1 expression in tumor tissue (TT) and immune cells (IC) in the primary BC tumor as well as in case of BC recurrence and/or metastasis to detect possible changes in PD-L1/PD-1 expression using immunohistochemstry. Methods: PD-L1/PD-1 expression was determined in histological specimens of 20 pat. with a recurrent non-muscle invasive BC (NMIBC – Cohort 1) as well as in 20 pat. with muscle-invasive BC (MIBC- Cohort 2) treated by radical cystectomy and appearance of metastases during follow up using commercial available assays (E1L3N, Cell Signaling/ Zytomed). Staining intensity was performed using the Cologne Score. PD-L1/PD-1 status was compared between primary tumor and metastatic/recurrent/progressive BC tissue and correlated with clinical data. Results: Cohort 1: In NMIBC (18m,2f) a recurrent tumor occurred after 25 mo (1-114). In the recurrent TT PD-L1 expression was higher compared to primary BC in 15%. In case of progression higher PD-L1 expression was detectable in 42.9%. IC showed higher PD-L1 expression in 50% of recurrent NMIBC and in 42% in case of progression. PD-1 expression on IC rose in 70% in recurrent and 71% in progressive NMIBC without correlation to time interval of appearance. Cohort 2: After curative cystectomy (17m,3f) metastases occurred after a median time of 20.5 mo (0-58). Comparing PD-L1 expression in cystectomy specimens and metastases we found differences in 52.9% (4x down/5x up). Expression of PD-L1 in primary BC tissue correlated significantly with the time to metastasis (p < 0.05). Conclusions: In case of metastasis after cystectomy as well as in recurrent/progressive NMIBC we found distinct variations in PD-L1/PD-1 expression in TT and IC. In MIBC primary PD-L1 status correlates with the time to metastasis. Whether PD-L1/PD-1 status can be helpful for clinical decisions (i.e. adjuvant therapy, instillation therapy) or as prognosticator have to be subject of further study.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Genitourinary (Nonprostate) Cancer: Publication Only

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Citation

J Clin Oncol 37, 2019 (suppl; abstr e16001)

DOI

10.1200/JCO.2019.37.15_suppl.e16001

Abstract #

e16001

Abstract Disclosures

Similar Abstracts

First Author: Mathilde Cancel

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Noninvasive assessment of programmed-death ligand-1 (PD-L1) in esophagogastric (EG) cancer using 18F-BMS-986229 PET.

First Author: Samuel Louis Cytryn

Abstract

2022 ASCO Annual Meeting

Pan-cancer landscape of CD274 (PD-L1) and PDCD1LG2 (PD-L2) structural variations.

First Author: Emily Louise Hoskins

First Author: Hidekazu Hirano